Compare MMS & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMS | PGEN |
|---|---|---|
| Founded | 1975 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 1997 | 2013 |
| Metric | MMS | PGEN |
|---|---|---|
| Price | $63.31 | $6.18 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $92.50 | $13.65 |
| AVG Volume (30 Days) | 647.7K | ★ 4.6M |
| Earning Date | 11-19-2026 | 11-12-2026 |
| Dividend Yield | ★ 2.08% | N/A |
| EPS Growth | ★ 10.42 | N/A |
| EPS | ★ 5.45 | 0.03 |
| Revenue | ★ $2,392,236,000.00 | $230,981,000.00 |
| Revenue This Year | N/A | $2,365.68 |
| Revenue Next Year | $2.89 | $85.75 |
| P/E Ratio | ★ $11.68 | $212.83 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $51.04 | $3.04 |
| 52 Week High | $100.00 | $8.98 |
| Indicator | MMS | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 71.39 | 34.75 |
| Support Level | $56.00 | $6.08 |
| Resistance Level | $70.49 | $7.30 |
| Average True Range (ATR) | 1.84 | 0.38 |
| MACD | 0.73 | -0.18 |
| Stochastic Oscillator | 94.55 | 2.57 |
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.